Business Context and Reporting Period
This Form 8-K is a current report filed by Altimmune, Inc. on August 17, 2017. The filing serves as supplemental disclosure following the Company's business combination (Merger) with the former Altimmune, Inc., completed on May 4, 2017. The primary purpose of this report is to announce a change in the date of the 2017 Annual Meeting of Stockholders and to provide updated deadlines for stockholder proposals.
Financial Metrics
This filing does not contain specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics for the current period. The document references Exhibit 99.2, which contains the Management's Discussion and Analysis of Financial Condition and Results of Operations for the fiscal year ended December 31, 2016, but the numerical values are not included in the text of this 8-K.
Material Changes
- Annual Meeting Date Change: The 2017 Annual Meeting of Stockholders has been rescheduled from September 7, 2017, to on or about October 13, 2017.
- Record Date Change: The record date for the 2017 Annual Meeting has been set to August 18, 2017.
- Proposal Deadlines: Due to the meeting date change exceeding the 30-day window from the one-year anniversary of the 2016 meeting, the deadline for stockholder proposals under Rule 14a-8 and director nominations under the Bylaws is now August 27, 2017.
Guidance, Outlook, and Risks
The filing contains no financial guidance, operational outlook, or discussion of risks and contingencies. It is strictly an administrative update regarding corporate governance procedures and meeting logistics. The Company notes that additional information regarding the Annual Meeting will be included in future proxy materials.
Key Facts for Investor Verification
- Verify the new Annual Meeting date of October 13, 2017, and the record date of August 18, 2017.
- Confirm the August 27, 2017 deadline for submitting stockholder proposals and director nominations to the Corporate Secretary.
- Review the referenced Form S-4/A (File No. 333-217034) for the detailed financial statements and business description incorporated by reference in Exhibits 99.1 and 99.2.
- Note that the Company is not an emerging growth company as indicated by the unchecked box in the filing.